Skip to content

Author: Ben Shaberman

Valproic Acid’s Effect Too Small in One-Year Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Valproic Acid’s Effect Too Small in One-Year Clinical Trial However, researchers identify a potentially powerful endpoint for evaluating emerging therapies in future studies. Results from a clinical trial sponsored by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI)…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Forty-Four High-Impact Retinal-Research Efforts Highlighted at FFB-Casey Innovation Summit For anyone wanting to know about the latest clinically focused research for inherited retinal diseases (IRDs), the Innovation Summit for Retinal Cell and Gene Therapy was the place to…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy ProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

ID Your IRD: A Free Genetic Testing Program for Eligible People with Inherited Retinal Diseases

Source: Foundation Fighting Blindness Blog – Eye on the Cure – ID Your IRD: A Free Genetic Testing Program for Eligible People with Inherited Retinal Diseases Genes are like the blueprint or code for determining who we are. We all have about 23,000 pairs of genes in most cells…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP

Source: Foundation Fighting Blindness Blog – Eye on the Cure – jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP These are retinal progenitors. The stem-cell therapy company jCyte is launching a Phase IIb clinical trial of its therapy for people with retinitis pigmentosa (RP). The trial…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest